Andy Vick, PhD
Charles River Laboratories
Dr. Andrew Vick has more than 20 years of experience working within the biotechnology and pharmaceutical industry in the fields of toxicology, nonclinical and clinical pharmacology, and drug disposition (PK/PD). Most recently, he has held senior leadership roles with Contract Research Organizations where he has provided strategic counsel to the biopharmaceutical industry.
Currently, Dr. Vick is responsible for financial, operational, and scientific oversight of all Midwest sites within Charles River’s North American Safety Assessment business. In this role, Dr. Vick oversees a biomedical staff of 3,000 who are involved in diverse aspects of nonclinical (toxicology, pharmacology, reproductive toxicology, laboratory sciences, etc.) and clinical (bioanalysis, PK/PD data analysis, etc.) development. These services include a full range of in vivo and in vitro testing capabilities that comply with global regulatory requirements in support of pharmaceuticals, animal health products, and agrochemical products. He also serves as the Executive Sponsor to several global pharmaceutical companies, where he provides strategic advice, customized program and study designs, regulatory advice, and risk mitigation tactics.
Dr. Vick earned his B.S. in Zoology and Ph.D. in Pharmaceutical Chemistry from The Ohio State University. He has continued his support of the University through service on the Dean’s Corporate Council for the College of Pharmacy, and he recently joined the Division of Pharmaceutical Chemistry as an Adjunct Professor. Dr. Vick also serves in the role of President-Elect for the American Association of Pharmaceutical Scientists.